KRAS and lung cancer: Furthermore, Cyrille et al. presented the mutational profiling of bone metastases from 44 patients with lung cancer, and showed that KRAS mutations were the most frequent (32% of cases) [25], suggesting that the RAS and PTNE/PIK3CA pathway is related to the metastatic process, especially bone metastasis, rather than primary tumor development.